News and events
- All
- Events
- Press releases
- Publications
All
- All
- Events
- Press releases
- Publications
ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19
ExeVir, which is developing single domain antibody therapies providing broad
September 1, 2021
Read More
ExeVir announces first subjects dosed Phase 1 clinical study of potent COVID-19 neutralizing antibody
ExeVir, which is developing single domain antibody therapies providing broad
August 18, 2021
Read More
ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments
ExeVir, which is developing single domain antibody therapies providing broad
July 15, 2021
Read More
ExeVir’s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern
ExeVir, which is developing single domain antibody therapies providing broad
July 13, 2021
Read More
ExeVir Announces Close of $50 million/ EUR42 million Series A Financing
ExeVir, which is developing single domain antibody therapies providing broad
March 16, 2021
Read More